Sequential management of postmenopausal health and osteoporosis: An update

Calaf Alsina, Joaquim; Cano, Antonio; Guañabens Gay, Núria; Palacios, Santiago; Cancelo Hidalgo, María Jesús; Castelo-Branco Flores, Camil; Larraínzar Garijo, Ricardo; Neyrp, José Luis; Nogués Solán, Xavier; Díez Pérez, Adolfo

doi:http://dx.doi.org/10.1016/j.maturitas.2023.107846

Sequential management of postmenopausal health and osteoporosis: An update

License

Citation

Calaf-Alsina J, Cano A, Guañabens N, Palacios S, Cancelo MJ, Castelo-Branco C, et al. Sequential management of postmenopausal health and osteoporosis: An update. Maturitas. 2023 Nov;177:107846. DOI: 10.1016/j.maturitas.2023.107846

Abstract

Increased life expectancy means that women are now in a hypoestrogenic state for approximately one-third of their lives. Overall health and specifically bone health during this period evolves in accordance with aging and successive exposure to various risk factors. In this review, we provide a summary of the approaches to the sequential management of osteoporosis within an integrative model of care to offer physicians a useful tool to facilitate therapeutic decision-making. Current evidence suggests that pharmacologic agents should be selected based on the risk of fractures, which does not always correlate with age. Due to their effect on bone turnover and on other hormone-regulated phenomena, such as hot flushes or breast cancer risk, we position hormone therapy and selective estrogen receptor modulators as an early postmenopause intervention for the management of postmenopausal osteoporosis. When the use of these agents is not possible, compelling evidence supports antiresorptive agents as first-line treatment of postmenopausal osteoporosis in many clinical scenarios, with digestive conditions, kidney function, readiness for compliance, or patient preferences playing a role in choosing between bisphosphonates or denosumab during this period. For patients at high risk of osteoporotic fracture, the "anabolic first" approach reduces that risk. The effect on bone health with these bone-forming agents or with denosumab should be consolidated with the subsequent use of antiresorptive agents. Regardless of the strategy, follow-up and treatment should be maintained indefinitely to help prevent fractures.